Clinical Trials, Research and Development
January 9, 2023
Via: Biopharma DiveArrowhead’s drug, called fazirsiran, is designed to treat alpha-1 antitrypsin deficiency, a genetic condition in which a mutant form of the namesake protein accumulates in liver cells, causing fibrosis and cirrhosis. Alpha-1 antitrypsin, or AAT, deficiency has become a target […]
September 21, 2023
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 1, 2023
August 30, 2023
September 19, 2023